23 June 2026
23 June 2026
ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.
The programme aims to resolve workflow obstacles, provide financial transparency, and optimise clinical trial conduct.
BioArctic will create a new drug candidate using its BrainTransporter platform and Lilly’s molecule.
The ongoing registrational trial will assess the efficacy and safety of Evategrel in both injection and oral capsule forms.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
